ADAPT Publications and PubMed Links
Click on the web address to access links
| # |
Publications and PubMed Links |
| 1 | Solomon SD, Wittes J, Finn PV, Fowler R, Viner J,
Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL,
Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E for the
Cross Trial Safety Assessment Group: Cardiovascular risk of
celecoxib in 6 randomized placebo-controlled trials, The cross trial
safety analysis. Circulation 2008;117:2104-13 http://www.ncbi.nlm.nih.gov/pubmed/18378608 |
| 2 | ADAPT Research Group: Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's disease anti-inflammatory prevention trial (ADAPT). PloS Clin Trials 2006; 1(7):e33.doi:10.1371/journal.pctr. http://www.ncbi.nlm.nih.gov/pubmed/17111043 |
| 3 |
ADAPT Research Group: Naproxen and celecoxib do not
prevent AD in early results from a randomized controlled trial.
Neurology 2007;68:1800-1808. http://www.ncbi.nlm.nih.gov/pubmed/17460158 |
4 |
Martin BK, Meinert CL, Breitner JCS for the ADAPT Research Group: Double placebo design in a prevention trial for Alzheimer's disease. Controlled Clin Trials 2002;23:93-99. http://www.ncbi.nlm.nih.gov/pubmed/11852171 |
5 |
Breitner JCS, Martin BK, Meinert CL: The Suspension of treatments in ADAPT: Concerns beyond the cardiovascular safety of celecoxib or naproxen. PloS Clin Trials 2006; 1(8):e41.doi:10.1371/journal.pctr.0010041. http://www.ncbi.nlm.nih.gov/pubmed/17192795 |
| 6 | Meinert CL, Breitner JCS: Chronic disease long-term drub prevention trials: Lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimer's & Demintia 2008;4:S7- S14. PubMed - in process |
| 7 |
Commentary to The American Journal of Medicine by Martin BK,
Breitner JCS, Evans D, Lyketsos CG, Meinert CL. The citation is: The Trialist, Meta-analyst, and Journal Editor: Lessons from ADAPT. The American Journal of Medicine 2007;120:192-193. http://www.ncbi.nlm.nih.gov/pubmed/17349436 |
|
8a |
Letter to the editor of the American Journal of Medicine from
Breitner J, Evans D, Lyketsos C, Martin B, Meinert C. The citation is: Letters ADAPT Trial Data. The American Journal of Medicine 2007;120,e3. |
| 8b |
The reply to the above letter to the editor from Salpeter SR,
Topol RJ. The citation is: Letter the Reply. The American Journal of Medicine 2007;120,e5. |
| 8c |
The reply by the editor-in-chief regarding the above exchange of
letters. The citation is: Alpert JS: Letter The Reply. The American Journal of Medicine 2007;120,e7. http://www.ncbi.nlm.nih.gov/pubmed/17349430 |
| 9 |
Kim SYH, Kin HM, McCallum C, Tariot PN: What do people
at risk for Alzheimer disease think about surrogate consent for
research? Neurology 2005;65:1395-1401. http://www.ncbi.nlm.nih.gov/pubmed/16275826 |
| 10 |
Green RC, DeKosky ST: Primary prevention trials in
Alzheimer disease. Neurology 2006;67(Suppl 3):S2-S5. http://www.ncbi.nlm.nih.gov/pubmed/17101930 |
| 11 |
ADAPT Research Group: Cognitive function over time in
the Alzheimer's disease anti-inflammatory prevention trial (ADAPT).
Arch Neurol 2008;65(7);(doi:10.1001/archneur.2008.65.7.nct70006). http://www.ncbi.nlm.nih.gov/pubmed/18474729 |
| 12 |
Martin B, Buffington ALH, Welsh-Bohmer KA, Brandt J
for the ADAPT Research Group: Time of day affects episodic memory in
older adults. Aging, Neurophychology, and Cognition 2008;15:146-164. http://www.ncbi.nlm.nih.gov/pubmed/17851985 |
| 13 |
Sabbach MN, Thompson N, Tweedy D, Stipho-Majeed S,
Kawas C, Connor DJ for the ADAPT group: Recruitment and retention
strategies for clinical trials in Alzheimer's disease.
Pharmaceutical Development and Regulation 2003;1:269-276. link unavailable |
| 14 |
Sparks DL, Sabbagh MN, Breitner JCS, Hunsaker III JC,
Is cholesterol a culprit in Alzheimer's disease. International
Phychogeriatrics 2003;15:153-159. http://www.ncbi.nlm.nih.gov/pubmed/16191233 |
Home
|
Centers |
Contacts |
Documents
|
Links |
Presentations
| Publications
